The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds and methods of making and using such compounds.

The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds and methods of making and using such compounds.

An organic electroluminescent device, which has a pair of electrodes and at least one organic layer including a luminescent layer between the pair of electrodes, wherein at least one layer between the pair of electrodes comprises at least one metal complex having a tridentate- or higher polydentate-chain structure ligand.

An organic electroluminescent device, which has a pair of electrodes and at least one organic layer including a luminescent layer between the pair of electrodes, wherein at least one layer between the pair of electrodes comprises at least one metal complex having a tridentate- or higher polydentate-chain structure ligand.

Disclosed herein is method for producing an iron dinuclear complex having two iron atoms bonded to each other via one oxygen atom and a ligand structure containing a Schiff base, a method which can produce an ester compound in high yield by the transesterification of an alcohol compound with a carboxylate ester even in the case where the raw material alcohol has a tertiary hydroxyl group which is usually difficult to esterify by transesterification, and a method which can produce a wholly esterified compound by transesterification catalyzed by an iron complex.

Described herein are compounds having a hydrogen-bonding group and optionally a functional group for binding (e.g., covalently binding) the compound to another compound (e.g., hyaluronic acid and/or gelatin). A compound of the present invention may have a structure represented by and/or comprising Formula I, Formula II, Formula III, Formula IV, Formula IV, Formula V, Formula V, Formula VI, Formula VII, and/or Formula VIII as described herein. Compositions including compounds of the present invention N along with methods of preparing and using the same are also described herein.

Described herein are compounds having a hydrogen-bonding group and optionally a functional group for binding (e.g., covalently binding) the compound to another compound (e.g., hyaluronic acid and/or gelatin). A compound of the present invention may have a structure represented by and/or comprising Formula I, Formula II, Formula III, Formula IV, Formula IV, Formula V, Formula V, Formula VI, Formula VII, and/or Formula VIII as described herein. Compositions including compounds of the present invention N along with methods of preparing and using the same are also described herein.

The present invention relates to a method for the production of d-erythro-sphingosine and analogs thereof, wherein the method comprises a step of condensing a compound of formula (2):

##STR00001## or a salt thereof,
wherein R.sup.1 is hydrogen, a C.sub.1-50 alkyl, preferably a C.sub.1-15 alkyl, more preferably a C.sub.10-15 alkyl, which may be saturated or contain one or more double and/or triple bonds, and/or which may contain one or more functional groups, the functional group being preferably selected from the group consisting of an alkoxy group, a secondary, or tertiary amine, a thioether, an acyloxy group, an acylamido group, a phosphorus containing functional group, a carboxyl group, or a carbonyl group, with a compound of formula (3):

##STR00002##

wherein the bond represents a double or a single bond, W is C, or C(OR.sup.4), Z is O, or OR.sup.5, provided that: when W is C, the bond is a double bond and Z is O, or when W is C(OR.sup.4), the bond is a single bond and Z is OR.sup.5, and
wherein R.sup.2 and R.sup.3 are independently selected from a saturated or unsaturated C.sub.1-6 alkyl, a saturated or unsaturated cycloalkyl, or an aryl, each of which may be substituted or unsubstituted, or wherein one of R.sup.2 and R.sup.3 is hydrogen, and the other rest is a saturated or unsaturated C.sub.1-6 alkyl, a saturated or unsaturated cycloalkyl, or an aryl, each of which may be substituted or unsubstituted, or wherein R.sup.2 and R.sup.3 may form a cyclic structure, R.sup.4 and R.sup.5 are independently selected from a C.sub.1-6 alkyl, a cycloalkyl, or an aryl, each of which may be substituted or unsubstituted.

The present invention relates to a method for the production of d-erythro-sphingosine and analogs thereof, wherein the method comprises a step of condensing a compound of formula (2):

##STR00001## or a salt thereof,
wherein R.sup.1 is hydrogen, a C.sub.1-50 alkyl, preferably a C.sub.1-15 alkyl, more preferably a C.sub.10-15 alkyl, which may be saturated or contain one or more double and/or triple bonds, and/or which may contain one or more functional groups, the functional group being preferably selected from the group consisting of an alkoxy group, a secondary, or tertiary amine, a thioether, an acyloxy group, an acylamido group, a phosphorus containing functional group, a carboxyl group, or a carbonyl group, with a compound of formula (3):

##STR00002##

wherein the bond represents a double or a single bond, W is C, or C(OR.sup.4), Z is O, or OR.sup.5, provided that: when W is C, the bond is a double bond and Z is O, or when W is C(OR.sup.4), the bond is a single bond and Z is OR.sup.5, and
wherein R.sup.2 and R.sup.3 are independently selected from a saturated or unsaturated C.sub.1-6 alkyl, a saturated or unsaturated cycloalkyl, or an aryl, each of which may be substituted or unsubstituted, or wherein one of R.sup.2 and R.sup.3 is hydrogen, and the other rest is a saturated or unsaturated C.sub.1-6 alkyl, a saturated or unsaturated cycloalkyl, or an aryl, each of which may be substituted or unsubstituted, or wherein R.sup.2 and R.sup.3 may form a cyclic structure, R.sup.4 and R.sup.5 are independently selected from a C.sub.1-6 alkyl, a cycloalkyl, or an aryl, each of which may be substituted or unsubstituted.

Novel compounds of formula (II) are disclosed. Compounds of formula (II) comprise ornithine derivatives or compounds that may metabolize to ornithine. Also disclosed are methods for the treatment of neurodegenerative diseases such as Alzheimer's Disease using compounds of formula (II). ##STR00001##